Viz.ai is First to Receive FDA 510(k) Clearance for AI Algorithm for Abdominal Aortic Aneurysm
Retrieved on:
Tuesday, March 21, 2023
Technology, Medical Devices, Health Technology, Cardiology, Software, Biotechnology, Health, General Health, Artificial Intelligence, Heart, Communication, Abdominal aortic aneurysm, Pulmonary embolism, AAA1, Food and Drug Administration, Aortic rupture, Intelligence, CTA, Multimedia, Risk, TriHealth, Viz, Death, Hospital, Triage, Rupture, AAA, MD, Patient, Physician, Blood, Korea Disease Control and Prevention Agency, Artificial intelligence, AI, FDA, Computed tomography angiography, Food, Disease, Medical device, Medical imaging
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its algorithm intended to detect suspected abdominal aortic aneurysm (AAA).
Key Points:
- Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its algorithm intended to detect suspected abdominal aortic aneurysm (AAA).
- The new artificial intelligence (AI) algorithm and clinical workflow solution will be a part of the VizTM AORTIC Module, an AI solution designed to accelerate treatment decisions for all aortic pathology.
- An abdominal aortic aneurysm is a bulge in the abdominal aorta, the main artery that carries blood from the heart to the rest of the body.
- Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals.